Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sapio Sciences Announces Exemplar LIMS for Clinical and Research NGS Labs

Published: Tuesday, February 25, 2014
Last Updated: Tuesday, February 25, 2014
Bookmark and Share
Purpose-built system handles the sample tracking and processing needs of clinical or research laboratories

Sapio Sciences has announced Exemplar LIMS for clinical and research NGS labs.   Exemplar NGS LIMS is a system built to handle the sample tracking and processing needs of clinical or research laboratories. Exemplar provides complete tracking of samples through the NGS pipeline from request through sample processing and results delivery. It provides automation integration as needed, along with preconfigured workflows, management level dashboards, full consumables management and support for regulatory compliance such as CLIA.

The dynamic nature of the NGS lab requires a LIMS that can adapt quickly to changing protocols and platforms. Exemplar is the most configurable LIMS at all levels, meaning that no matter what technology you introduce into your lab or what your requirements are, you can be confident that Exemplar can meet your needs.

When evaluating a LIMS, labs should choose a system that:

Is fully web based for complete end user usage and configuration and is usable on tablet computers.
Tracks volumes of samples through the pipeline
Has pre-built, CLIA standard, NGS workflows
Fully tracks aliquot and derivative lineage
Tracks samples and workflows throughout the pipeline.
Collects quality control data and integrates with all leading QC genomics instruments.
Can fully track consumables including amount remaining in inventory and expiration dates.
Is highly configurable to easily alter existing workflows and when creating new ones.
Includes graphical dashboards of lab activity
Is highly scalable to handle anticipated concurrent users and sample volumes for many years
Can support any additional lab process outside the NGS arena
This extent of this list is daunting for a new MDx company to consider as a thorough implementation of these features could require 4 or more software solutions and years of work. New labs also need to get CLIA certification and may also need to operate under GLP and/or be a validated lab per FDA Part 11 specifications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!